Tyson Eliot Marshall Sells 12,878 Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) Stock

Key Points

• Tyson Eliot Marshall, the General Counsel of Alphatec Holdings, sold 12,878 shares at $12.00 each, totaling $154,536, reducing his ownership by 2.74% to 456,423 shares.
• Alphatec reported a $0.02 earnings per share for the last quarter, surpassing estimates and achieving 27.5% year-over-year revenue growth.
• Recent institutional investments in Alphatec have increased significantly, with key investors boosting their stakes, indicating strong confidence in the company's future.

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) General Counsel Tyson Eliot Marshall sold 12,878 shares of the stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $12.00, for a total value of $154,536.00. Following the transaction, the general counsel directly owned 456,423 shares of the company's stock, valued at approximately $5,477,076. This trade represents a 2.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Tyson Eliot Marshall also recently made the following trade(s):

• On Tuesday, August 5th, Tyson Eliot Marshall sold 18,092 shares of Alphatec stock. The stock was sold at an average price of $14.91, for a total value of $269,751.72.
• On Thursday, July 10th, Tyson Eliot Marshall sold 1,500 shares of Alphatec stock. The stock was sold at an average price of $12.00, for a total value of $18,000.00.

Alphatec Price Performance

ATEC traded up $0.07 during midday trading on Friday, reaching $14.97. 1,745,343 shares of the company's stock were exchanged, compared to its average volume of 2,816,030. Alphatec Holdings, Inc. has a 1-year low of $4.88 and a 1-year high of $15.46. The stock has a market capitalization of $2.22 billion, a PE ratio of -13.25 and a beta of 1.05. The company has a debt-to-equity ratio of 23.22, a current ratio of 2.88 and a quick ratio of 1.77. The business's 50-day moving average price is $11.63 and its 200 day moving average price is $11.28.

Alphatec (NASDAQ:ATEC - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The medical technology company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.08. Alphatec had a negative return on equity of 1,657.19% and a negative net margin of 24.33%. The firm had revenue of $185.54 million during the quarter, compared to the consensus estimate of $178.85 million. During the same period in the previous year, the firm posted ($0.29) EPS. The company's quarterly revenue was up 27.5% compared to the same quarter last year. As a group, equities analysts anticipate that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ATEC. Lake Street Capital upgraded shares of Alphatec to a "buy" rating and set a $18.00 price target for the company in a report on Monday, June 16th. HC Wainwright restated a "buy" rating and set a $20.00 target price on shares of Alphatec in a research report on Monday, April 14th. Barclays reiterated an "overweight" rating and set a $22.00 price target (up from $21.00) on shares of Alphatec in a research report on Monday, August 4th. Piper Sandler reissued an "overweight" rating and set a $15.00 price target (up previously from $13.00) on shares of Alphatec in a research note on Friday, May 2nd. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $16.00 price objective on shares of Alphatec in a research note on Friday, May 2nd. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $18.50.

Institutional Trading of Alphatec

Several institutional investors and hedge funds have recently made changes to their positions in ATEC. Raymond James Financial Inc. purchased a new stake in Alphatec during the 4th quarter worth about $358,000. Commonwealth Equity Services LLC boosted its stake in shares of Alphatec by 55.9% during the 4th quarter. Commonwealth Equity Services LLC now owns 36,929 shares of the medical technology company's stock worth $339,000 after purchasing an additional 13,246 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new stake in shares of Alphatec during the fourth quarter worth about $228,000. LPL Financial LLC grew its holdings in shares of Alphatec by 19.9% during the fourth quarter. LPL Financial LLC now owns 413,235 shares of the medical technology company's stock worth $3,793,000 after buying an additional 68,516 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Alphatec by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 5,968,980 shares of the medical technology company's stock valued at $54,795,000 after buying an additional 47,797 shares during the last quarter. 66.35% of the stock is currently owned by hedge funds and other institutional investors.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.